- Home
- MTVA vs LYRA Comparison
MTVA vs LYRA Comparison
Compare MTVA & LYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTVA
- LYRA
- Stock Information
- Founded
- MTVA 2014
- LYRA 2005
- Country
- MTVA United States
- LYRA United States
- Employees
- MTVA N/A
- LYRA N/A
- Industry
- MTVA
- LYRA Medical/Dental Instruments
- Sector
- MTVA
- LYRA Health Care
- Exchange
- MTVA NYSE
- LYRA Nasdaq
- Market Cap
- MTVA 16.8M
- LYRA 13.5M
- IPO Year
- MTVA N/A
- LYRA 2020
- Fundamental
- Price
- MTVA $1.60
- LYRA $0.21
- Analyst Decision
- MTVA Strong Buy
- LYRA Buy
- Analyst Count
- MTVA 1
- LYRA 5
- Target Price
- MTVA $12.00
- LYRA $4.50
- AVG Volume (30 Days)
- MTVA 23.0K
- LYRA 907.8K
- Earning Date
- MTVA 03-27-2025
- LYRA 03-20-2025
- Dividend Yield
- MTVA N/A
- LYRA N/A
- EPS Growth
- MTVA N/A
- LYRA N/A
- EPS
- MTVA N/A
- LYRA N/A
- Revenue
- MTVA N/A
- LYRA $1,471,000.00
- Revenue This Year
- MTVA N/A
- LYRA N/A
- Revenue Next Year
- MTVA N/A
- LYRA N/A
- P/E Ratio
- MTVA N/A
- LYRA N/A
- Revenue Growth
- MTVA N/A
- LYRA 3.37
- 52 Week Low
- MTVA $1.51
- LYRA $0.16
- 52 Week High
- MTVA $6.75
- LYRA $6.79
- Technical
- Relative Strength Index (RSI)
- MTVA N/A
- LYRA 57.63
- Support Level
- MTVA N/A
- LYRA $0.19
- Resistance Level
- MTVA N/A
- LYRA $0.22
- Average True Range (ATR)
- MTVA 0.00
- LYRA 0.01
- MACD
- MTVA 0.00
- LYRA 0.00
- Stochastic Oscillator
- MTVA 0.00
- LYRA 66.75
About MTVA METAVIA INC
MetaVia Inc Formerly NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused predominantly on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. The company has two primary programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH), and obesity. Its product pipeline includes DA-1241 which is a novel G-Protein-Coupled Receptor 119 (GPR119) and DA-1726 which is a novel oxyntomodulin (OXM) analog. The company also has four legacy therapeutics programs designed to impact a range of indications in viral, neurodegenerative, and cardiometabolic diseases: ANA001, NB-01, NB-02, and Gemcabene.
About LYRA Lyra Therapeutics Inc.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.